ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,320.76
0.43%
Dow Jones
42,313.00
0.33%
Gold vs US Dollar
2,652.77
-0.74%
Brent Oil
71.98
1.45%
Bitcoin
65,879.52
1.07%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Palisade Bio Inc (PALI)

  7. Palisade Bio Inc (PALI) News

Palisade Bio (PALI)

Palisade Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PALI
DateTimeSourceHeadlineSymbolCompany
27/09/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PALIPalisade Bio Inc
25/09/202413:00GlobeNewswire Inc.Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative ColitisNASDAQ:PALIPalisade Bio Inc
16/09/202413:00GlobeNewswire Inc.Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision TherapiesNASDAQ:PALIPalisade Bio Inc
05/09/202413:00GlobeNewswire Inc.Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient StratificationNASDAQ:PALIPalisade Bio Inc
19/08/202413:00GlobeNewswire Inc.Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PALIPalisade Bio Inc
13/08/202413:05GlobeNewswire Inc.Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PALIPalisade Bio Inc
12/08/202421:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PALIPalisade Bio Inc
08/08/202413:00GlobeNewswire Inc.Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative ColitisNASDAQ:PALIPalisade Bio Inc
31/07/202414:15GlobeNewswire Inc.Palisade Bio Participates in Virtual Investor “What this Means” SegmentNASDAQ:PALIPalisade Bio Inc
29/07/202413:30GlobeNewswire Inc.Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108NASDAQ:PALIPalisade Bio Inc
19/07/202413:30GlobeNewswire Inc.Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108NASDAQ:PALIPalisade Bio Inc
16/07/202401:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
16/07/202401:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
16/07/202401:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
08/07/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PALIPalisade Bio Inc
24/06/202414:00GlobeNewswire Inc.Palisade Bio to Participate in the Virtual Investor Closing Bell SeriesNASDAQ:PALIPalisade Bio Inc
21/06/202413:15GlobeNewswire Inc.Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life SciencesNASDAQ:PALIPalisade Bio Inc
13/06/202402:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
13/06/202402:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
11/06/202413:30GlobeNewswire Inc.Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108NASDAQ:PALIPalisade Bio Inc
10/06/202414:15GlobeNewswire Inc.Palisade Bio to Present at the Virtual Investor Pitch ConferenceNASDAQ:PALIPalisade Bio Inc
31/05/202400:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
31/05/202400:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
29/05/202420:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
28/05/202411:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
22/05/202421:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
22/05/202421:50Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:PALIPalisade Bio Inc
22/05/202421:48Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PALIPalisade Bio Inc
22/05/202421:45Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PALIPalisade Bio Inc
21/05/202413:30GlobeNewswire Inc.Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse ModelsNASDAQ:PALIPalisade Bio Inc
 Showing the most relevant articles for your search:NASDAQ:PALI

Your Recent History

LSE
THUS
Thus
USOTC
PEBC
Peoples Bancorp (PK)
TG
A3KTS7
Nemak
BIT
UB26GP
UniCredit Bank
USOTC
PGTRF
Pegatron (PK)
TG
APCH
Apple Computer
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved